Johnson & Johnson strengthens nipocalimab’s FDA case with rapid hemoglobin improvement
The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.
